Final Height in Patients With CAH

NCT04293133 | Unknown

• 1 other identifier: CAH
• Study Type: observational
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Congenital adrenal hyperplasia (CAH) is the most common inherited disorder in the adrenal gland in children. Growth is usually affected in CAH patients either due to the disease itself or treatment consequences.

Conditions

Congenital Adrenal Hyperplasia

Outcome Measures

Primary Outcomes (1)

• Final height in patients with congenital adrenal hyperplasia

  Target height(TH) will be calculated using the formula: \[maternal height + paternal height - 13 cm for girls and + 13 cm for boys\]/2

  Baseline

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients having a documented history of classical CAH.

You may qualify if:

• Patients having a documented history of classical CAH.

You may not qualify if:

• Patients with non classical CAH.
• Patients treated with growth hormone.
• Chronic use of medications unrelated to CAH which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline.
• Other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease.
• Other causes of adrenal insufficiency.

Sponsors & Collaborators

• Ain Shams University: lead

Related Publications (2)

• Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child. 1995 Jul;73(1):25-9. doi: 10.1136/adc.73.1.25.

  PMID: 7639544 BACKGROUND

• Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol. 2004 Nov;151 Suppl 3:U77-82. doi: 10.1530/eje.0.151u077.

  PMID: 15554890 BACKGROUND

MeSH Terms

Conditions

Adrenal Hyperplasia, Congenital

Condition Hierarchy (Ancestors)

Adrenogenital Syndrome; Disorders of Sex Development; Urogenital Abnormalities; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Steroid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases; Adrenal Gland Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Rana Ahmed

  Ain Shams University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mohammed Kamel

CONTACT

+2001285819500; kamelasbour@gmail.com

Marwa Magdy

CONTACT

+200100536847; dr.ranahakim@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Final height in patients with congenital adrenal hyperplasia

Study Record Dates

• First Submitted: March 2, 2020
• First Posted: March 3, 2020
• Study Start: March 11, 2020
• Primary Completion: August 11, 2020
• Study Completion: September 11, 2020
• Last Updated: March 3, 2020

Record last verified: 2020-03